Harm Reduction Policies Essential to Prevent Cancer, Say I-Com and MEPs
I-Com, the Institute for Competitiveness, yesterday hosted a landmark roundtable in the context of Europe’s Beating Cancer Plan, summarised here, bringing together policymakers from across the political spectrum, academics and scientists to present the findings of their study on best practices to beat cancer.
During the roundtable, the discussion analysed best practices and successes of harm reduction policies across Europe. Enabling citizens to live healthier lifestyles by making less risky products accessible, such as vaping devices for smokers, by conducting education and awareness campaigns about responsible alcohol consumption and by building infrastructure promoting physical activity are examples of the core ideas driving the evidence-based approach behind harm reduction policy. During the public consultations on the Beating Cancer Plan, 20% of submissions highlighted harm reduction’s potential role.
Dolors Montserrat, Hosting MEP and a member of the Special Cancer Committee, said:
“I want to thank I-Com for the study just published that highlights how prevention policies aimed at reducing risk factors have a lot of potential to help Europe beat cancer. The Special Cancer Committee and the European Parliament welcome the study findings aimed to contribute to the future actions orientation of the Beating Cancer Plan. Our wish is for the Parliament to play a key role in developing the Plan in effective and fruitful coordination with the European Commission.”
Commenting on the roundtable, Stefano da Empoli, President of I-Com, said:
“We were delighted to present our recommendations on how harm reduction can support the prevention of cancer. It is now clear that public health experts, policymakers and academics all support the inclusion of harm reduction policies to help prevent cancer and mitigate the harm caused by tobacco, alcohol and unhealthy diets. Legislators must, at all times, keep patients at the forefront of their minds. Now is the time to embrace harm reduction.”
Margratis Schinas, European Commissioner for Promoting the European Way of Life, said:
“Our aim for the Plan is that cancer should no longer mean chances
fading away, dropping out from projects, or stigmatisation.
Instead, one day, cancer shall mean accessible treatment, recovery
and, therefore, life opportunities for all affected people.
And this is possible. Up to 40% of cancers can be prevented.”
I-Com’s recommended best practices in minimising the harms caused by alcohol, tobacco and nutrition, include reducing the availability of alcohol, increasing the availability of smokeless tobacco products and building infrastructure promoting physical activity.
ABOUT I-COM
The Institute for Competitiveness (I-Com) is an Italian independent think tank based in Rome and Brussels, founded in 2005 by a group of scholars, professionals and managers. I-Com aims at influencing the public debate at the national, European and international level, analysing the most important drivers for competitiveness and growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929006173/en/
Contact information
MEDIA QUERIES
Mattia Ceracchi, Head of EU Affairs, I-Com
ceracchi@i-com.it
+ 32 (0) 22347882
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
